Amicus Therapeutics Commences Phase 1 Clinical Trials For AT2220 For Pompe Disease

... Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced that it has commenced Phase 1 clinical trials for AT2220 for the treatment of Pompe disease, following acceptance of an investigational new drug application (IND) by the U.S. [click link for full article] ...